Global left ventricular (LV) ejection fraction (LVEF) has been used as a measure of improvement in LV function following cell therapy. Although the impact of cell therapy on LVEF in short-and long-term follow-up has been generally positive, there is concern that research evaluating regional therapeutics (e.g., cell or gene therapy) may require analysis of regional LV function localized to the site of intervention.
G lobal left ventricular ejection fraction (LVEF) has been used as the predominant measure to assess LV function following cell therapy. However, the impact of cell therapy on LVEF in short-and long-term follow-up has been variable. The National Institutes of Health identified clinical aspects of cellbased therapy as an unmet area of need and established the Cardiovascular Cell Therapy Research Network (CCTRN). The primary goal of the CCTRN is to conduct multiple collaborative cell therapy clinical protocols. CCTRN investigators recognized that many imaging-based parameters of LV function are available to quantify the effect of regional cell therapy, but the basis for choosing one over another had not been critically examined. Accordingly, the uniqueness of this document is to review the advantages and limitations of various noninvasive imaging modalities available to quantify global and regional LV mechanical function. From this information, we articulate why the CCTRN investigators reached a consensus on which measures of LV function have the potential to most successfully predict clinically meaningful improvement in patient outcomes after regional therapeutic intervention. CCTRN protocols include acquisition of cardiac magnetic resonance (CMR) and echo images with response variables quantified at dedicated echo and CMR core laboratories with results submitted to a central data coordinating center. Because the CCTRN will collect many variables provided by multiple modalities, its work should help answer which measures of regional LV function are most clinically relevant.
Global LV Assessment
Myocardial contraction is a complex process that occurs in 4 dimensions in both a global and segmental domain. Since segmental myocardial contraction has been difficult to measure in patients, global measures to assess LV performance have often been used. It remains unclear whether measures of global LV pump performance or regional LV function are most predictive of cardiovascular (CV) outcomes. Methods of global LV assessment. Global LV function is most frequently reported as LVEF, which refers to the percentage of the LV end-diastolic volume ejected with each contraction. LVEF can be determined by multiple imaging modalities, including echocardiography, ventriculography, CMR imaging, computed tomography, and radionuclide angiography. Although CMR is widely regarded as the reference standard for measurement of LVEF, echocardiography is most frequently used, being inexpensive, portable, and without contraindications. However, there are limitations with echocardiographic assessment of LVEF. Foreshortening of the apical views will result in an underestimate of LV volumes and overestimate of LVEF, whereas the presence of regional wall motion abnormalities can lead to errors when limited imaging planes are used to assess LVEF. Additionally, there is more interstudy variability of LVEF with echocardiography compared with CMR (1). Due to the different handling of endocardial trabeculations, echocardiography typically results in lower volumes than those determined with CMR. Use of microbubbles for contrast can significantly improve endocardial visualization by echocardiography and provide volume estimates that more closely approximate those determined with computed tomography (2) . Threedimensional (3D) echocardiography can also improve LVEF assessment, particularly in the presence of regional dyskinesis (3). However, endocardial definition is sometimes suboptimal with 3D acquisition. Determination of LVEF with CMR may overcome the challenge of regional wall motion abnormalities by utilizing a series of short-axis imaging planes that incorporate the entire LV. However, CMR is expensive, less widely available, and at the present time, prohibited in patients with electronic devices. This may limit its usefulness among patients with advanced heart failure enrolled in cell therapy trials who have pacemakers or defibrillators. Applications of global LV assessment. Assessment of global LVEF provides a robust predictor of risk for CV outcomes, with the potential to significantly influence patient management. For example, in heart failure patients, the risk for all-cause mortality is increased by 39% for every 10% reduction in LVEF below 45% (4) . Similarly, CV death and heart failure hospitalization rates declined with increasing LVEF up to 45%. The discriminatory effect of LVEF for prediction of outcomes is limited in patients with an LVEF Ͼ45%. This lack of discrimination may be due to inability to detect subtle abnormalities of segmental LV systolic function not contained within the imaging planes used to assess LVEF. An assessment of global LV function based on the composite of function in each segment has the potential to overcome these limi- tations and is superior to LVEF in predicting risk for adverse outcome (5) . It is noteworthy that the LVEF in many patients enrolled in CV cell therapy trials exceeds this 45% threshold (6) .
Although global LVEF may improve after intervention, such improvements may be subtle. LVEF improved only 1% to 5% in patients with otherwise evidence-documented life-saving therapies (e.g., coronary revascularization, angiotensin-converting enzyme inhibitors, angiotensin receptor blockade, or beta blockade) after acute myocardial infarction (7). Thus, small changes in LV function may translate to meaningful improvement in clinical outcomes, but global LVEF may be an insensitive measure of this change in outcome. This is supported by the findings in the REPAIR-AMI (Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction) study, which demonstrated that adverse outcomes were significantly reduced among patients receiving cell therapy compared with placebo, despite only a small improvement in LVEF (6) .
As compared with revascularization alone, additional improvements in LVEF after cell therapy and revascularization have ranged from 0% to as much as a 6% (Table 1) (8 -13) . If global LVEF is to be used as the measure of interest in cell therapy trials, use of an imaging modality that limits need for geometrical or 3D assumptions, such as with CMR or 3D echocardiography, would be preferred. However, important, but subtle, changes in LV function after cell therapy may not be detected with global assessment of LV function, whereas regional assessment of LV function may enhance detection of these important changes.
Regional LV Assessment
Regional LV assessment can include evaluation of mechanical function, segmental perfusion, and tissue characterization. Segmental perfusion and tissue characteristics are important components of regional myocardial function after acute ischemic injury, as the presence of microvascular obstruction and the ratio of edematous to infarcted tissue predict improvement in contractile function and future CV events (14-16). However, due to space limitations, the current review focuses on measures of mechanical function. Assessment of regional LV mechanical function can be performed with quantification of both regional EF or segmental myocardial contraction. Regional EF offers the advantage of summarizing the end effect of the complex deformations in adjacent myocardial segments, whereas quantification of segmental myocardial contraction allows for direct evaluation of mechanical properties of selected myocardial segments that may be improved following cell therapy. Regional EF. Regional EF has been determined with nuclear, CMR, and echocardiographic techniques (17, 18) , and with each imaging modality, has been defined by different methods. For example, regional EF measured with CMR can be as simple as the comparison of the end-diastolic and end-systolic volumes constrained by the endocardial border in a single short-axis CMR image. This method was employed in the BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial as regional EF was determined only in slices that contained late contrast enhancement (13) . Other studies have reported regional EF using the fixed centerpoint method. Briefly, the ventricle is divided into a number of wedge-shaped subvolumes radiating from the LV long axis, and the proportional change in each subvolume from diastole to systole is reported as the regional EF. Finally, the CCTRN CMR core laboratory divides the LV volume into thirds and measures the enddiastolic and end-systolic volume within each of the apical, mid, and basal regions. Regional EF strongly correlates with the function of adjacent myocardial segments as determined by wall motion, wall thickening, and infarct transmurality. Thus, regional EF measured by CMR in acute myocardial infarction patients was significantly lower in regions with infarction versus regions with no infarction in adjacent myocardial segments (17) .
Regional EF measured with radionuclide ventriculography has been shown to improve with revascularization (19) . Additionally, regional EF measured by CMR did improve after revascularization for acute myocardial infarction, whereas wall thickening did not (17) . Regional EF may also be a sensitive marker of improvement after cell therapy. In the BOOST trial, patients who received intracoronary bone marrow cells had significant improvement in regional EF at 6 months compared with those who did not receive cells (13) . However, this difference was not present at 18 months, largely due to delayed improvement in regional EF in the control group (12) . In BOOST, regional EF and global EF improved in a similar degree in patients with cell therapy. Therefore, although regional EF appears more sensitive than wall thickening in detection of improved LV function after traditional revascularization, it remains unclear whether regional EF will advance detection of improved LV function following cell therapy. Segmental myocardial contraction. Assessment of regional myocardial function can be improved by characterization of segmental deformation throughout the heart. This is complicated because the LV has a complex architecture with a left-handed helix in the epicardium, a right-handed helix in the endocardium, and nearly circumferential fibers in the midwall (20) . This architecture leads to 4 contraction patterns during systole: radial wall thickening; circumferential contraction; descent of the base of the heart toward the apex with longitudinal shortening; and torsion, as epicardial helical fibers rotate the apex counterclockwise (as viewed from the apex) relative to the base (21) . There are numerous methods for quantifying each of these, but it is unclear which will prove most accurate for characterizing the response to cell therapy.
Among the oldest methods to quantify radial wall thickening is the centerline method, which measures myocardial thickening relative to the center of the wall (22) . Wall thickening is traditionally reported as average thickening within each of the American Heart Association 16 or 17 segments. However, the higher resolution afforded by advanced noninvasive imaging techniques, such as CMR, coupled with increased processing power for image reconstruction and analysis, provide new opportunities. For example, the CCTRN CMR core laboratory has chosen to analyze 8 to 12 short-axis slices with 100 chords per slice. As a result, approximately 1,000 chords are analyzed for each study, with wall thickening and motion calculated for each chord using the centerline method. Methods of strain imaging. A more advanced approach to describe regional contraction is through use of strain imaging, which characterizes myocardial tissue deformation. Mathematically, strain is a 3 ϫ 3 tensor, which captures both linear deformation (stretching or compression along the 3 principal axes) and shear (sliding of 1 tissue plane against another). In the heart, strain is typically referenced to the coordinate system of the LV, yielding radial, circumferential, and longitudinal strain components (23) (Fig. 1) . In addition to these 3 components of myocardial segment deformation, strain imaging allows for quantification of LV torsion, which is an important component of normal LV mechanics (24) . Regional EF correlates strongest with circumferential and longitudinal strain compared with wall thickening, suggesting that these parameters may have a greater impact on stroke volume and cardiac output than wall thickening alone (25) . 
CARDIAC MAGNETIC RESONANCE.
The most frequent approach to CMR strain imaging is by tracking a grid of magnetic tags formed by inverting protons in specific locations throughout the image (26) . Radiofrequency tagging is accomplished by altering the net magnetization of the tissue with carefully designed radiofrequency pulses (27) . Each tag is created as a 3D plane that extends through the tissue, and it is seen as a dark line (Fig. 2) . Because these tags result from alterations of magnetization of tissue itself, the motion of the tags matches the motion of underlying tissue, which can be tracked over time to quantify myocardial deformation. Wall thickening determined by tagged CMR correlates with wall-thickening measures by sonomicrometry, although systolic thickening appears to be systematically higher with tagged CMR versus sonomicrometry (Table 2) (17,18,28 -34) .
ECHOCARDIOGRAPHY. Unfortunately, CMR strain measurements are rarely made in clinical practice, due to cost, lengthy time of analysis, and contraindications for patients with implanted devices. Echocardiography can be used to calculate regional myocardial strain by 2 basic techniques: analysis of velocity from tissue Doppler and tracking of myocardial speckles. Tissue Doppler maps the component of velocity directed toward the transducer throughout the image. The spatial derivative of velocity along the scan line yields the strain rate, the temporal integral of which yields strain (35) . However, this technique is dependent on alignment of the ultrasound beam in the appropriate region of interest. Therefore, only certain axes of deformation can be determined in a limited number of myocardial segments.
Speckle tracking echocardiography (STE) overcomes many limitations of tissue Doppler techniques.
Figure 2. Example of Cardiac Magnetic Resonance Tagging
The tags are seen as dark lines. The deformation of the tag lines can be seen at end-systole. STE is based on tracking fairly constant speckle patterns created by interference of the ultrasound beam with microscopic structures within the myocardium (28) . Because STE analyzes routinely acquired grayscale images, it is, unlike tissue Doppler, angle independent and can be quickly and reproducibly performed offline after study completion. STE allows strain and strain rate measurement along all 3 orthogonal axes of ventricular deformation for all LV segments. Both tissue Doppler and STE modestly correlate with CMR tagging and sonomicrometry (28, 36) . However, image quality, frame rate, and depth and direction of movement of the tracked speckles can impact fidelity of the analysis. At times as much as 10% to 20% of data in a single study may be "too noisy" for appropriate analysis (37, 38) . Recently, STE has been applied to 3D echocardiograms (39) . Whether the advantage of being able to track speckles wherever they move in 3D space outweighs the much lower frame rate of 3D echo and associated further impairment in the fidelity of the analysis, remains to be determined. A limitation of both 2D and 3D STE is that it is very vendor specific, typically applied to images stored in proprietary ultrasound scan line formats. There are limited data demonstrating equivalence between strain measurements obtained by different vendors. The American Society of Echocardiography and the European Association of Echocardiography have formed a task force with industry to address these concerns, and hopefully, this will make STE more widely applicable to images stored in standard Digital Imaging and Communications in Medicine format.
Applications of strain imaging in ischemic heart disease.
These newer measures of segmental myocardial contraction have been used in many different ways to evaluate patients with ischemic heart disease. Echocardiographic and CMR strain imaging may assist with identification of ischemic tissue (Table 3 ) (37,40 -43) . Additionally, strain imaging provides estimation of segmental myocardial viability and likelihood of improvement with revascularization (37) . Furthermore, strain imaging has demonstrated the ability to predict final infarct size and LV remodeling after infarction (42, 43) . Therefore, strain analysis may assist in identifying those patients who would benefit from an early, invasive strategy that includes revascularization and/or cell therapy. Importantly, strain imaging may increase the sensitivity to detect improvement of LV function after regional therapy and may enhance localization of infarcted tissue that might benefit from such therapy. Markers of improved function after cell therapy. Assessment of improvement in LV function after cell therapy may be a more difficult task than simply assessing a change in overall LVEF. This may be particularly true in the setting of acute myocardial infarction where hyperdynamic contraction of remote regions may elevate LVEF. Quantified measures of LV segmental myocardial strain may allow for better recognition of these early and subtle improvements in myocardial function in the periinfarct region following cell therapy. For example, early after reperfusion for acute myocardial infarction, there was no significant difference in the improvement in LVEF comparing patients treated with cells and controls (9) . However, strain of infarcted segments improved significantly more in the cell-treated group. In another pilot study, 12 patients who received intramyocardial autologous cells during coronary artery bypass surgery were evaluated with echocardiography before and 1 year CAD ϭ coronary artery disease; IHD ϭ ischemic heart disease; LVEF ϭ left ventricular ejection fraction; MI ϭ myocardial infarction; revasc. ϭ revascularization; other abbreviations as in Tables 1 and 2 .
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after injection (44) . On average, longitudinal strain increased 40% in segments that underwent revascularization without cell therapy, but increased 93% in segments that underwent revascularization with cell therapy (p ϭ 0.002). In cell-treated segments, visual estimates of segmental myocardial contractility increased 5%, whereas longitudinal strain increased 159% (p ϭ 0.0001). Although these exploratory studies suggest that strain imaging may be more sensitive in detecting improvement in LV function after cell therapy, not all studies have demonstrated strain to be superior to LVEF as a marker of improvement after cell therapy. In the ASTAMI (Autologous Stem Cell Transplantation in Acute Myocardial Infarction) trial, improvements in LVEF and longitudinal strain were no different in cell-treated patients compared with those who received placebo (8) . In this study, strain measurements may not have improved because of the lack of true improvement in myocardial function. Future studies comparing the ability of strain and LVEF to detect improvement following cell therapy are clearly needed. As reported above, regional EF may also be a sensitive marker of improvement in LV function after cell therapy. Because comparative studies are lacking, it remains unclear whether regional EF or strain will be the most sensitive measure of improved LV function after cell therapy. Also unknown are the amounts and types of improvements in these regional measures of LV function that might predict improvements in morbidity and mortality. For example, is improvement in apical regional EF or strain more relevant than improvement in basal regional LVEF or strain? Data from the CCTRN core labs could help answer these questions.
Conclusions and Future Directions
Although the impact of cell therapy on global LVEF in short-and long-term follow-up has been variable, overall, the results show modest improvement. To better assess the effect of regional therapeutics (such as cell or gene therapy), we propose that future research include analysis of regional LV function localized to the site of intervention (Table 4) . Regional LV mechanical function can be quantified with regional EF or measures of segmental myocardial contraction. Segmental contraction can be evaluated by indices of wall thickening or with CMR or echocardiographic strain imaging.
Changes in regional EF and myocardial segmental strain appear to offer an enhanced ability to detect subtle improvements in LV function after intervention. Although regional EF and strain, compared with wall thickening, may enhance sensitivity for detecting improvement in LV function, it remains unclear whether such measures are better able to predict improvement in clinical outcomes. Accordingly, the CCTRN will implement use of high-definition wall-thickening measurements in addition to regional EF measurements. The CCTRN will consider incorporating strain imaging in future projects, and will aim to determine which measures of regional LV mechanical function best link with clinical outcomes. Further, assessment of LV function after cell therapy may not be appropriately addressed with a single measure of a single region. Assimilation of all of the regional information provided to the CCTRN central data coordinating center should allow for the investigation of new indices or computational models to help better understand the impact of cell therapy on LV function.
